U.S. markets closed

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed Price. Currency in AUD
0.3750+0.0150 (+4.17%)
As of 11:23AM AEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3600
Bid0.3700 x 1092600
Ask0.3750 x 5097500
Day's Range0.3600 - 0.3750
52 Week Range0.3400 - 1.4250
Avg. Volume6,633,639
Market Cap305.123M
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)-0.1700
Earnings DateAug 30, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.02
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MSB.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

      NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee. Ms Bell joined the Board in August 2022, and is a banking and finance lawyer with 30 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Austral

    • The Wall Street Journal

      Health Care Roundup: Market Talk

      Find insight on Ikena Oncology, ATS’s acquisition of Avidity Science, and more in the latest Market Talks covering the Health Care sector.

    • GlobeNewswire

      Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease (SR-aGVHD), following a Type A meeting held with the United States Food and Drug Administration (FDA). FDA clarified that the key remaining issue for pedi